Fennec Pharmaceuticals Stock Revenue
| FENC Stock | USD 7.84 0.34 4.16% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Fennec Pharmaceuticals' long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 47.5 M | 49.9 M |
Fennec | Revenue | Build AI portfolio with Fennec Stock |
Fennec Pharmaceuticals Company Revenue Analysis
Fennec Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Fennec Pharmaceuticals Revenue | 47.54 M |
Most of Fennec Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fennec Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Fennec
Projected quarterly revenue analysis of Fennec Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Fennec Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Fennec Pharmaceuticals' stock price.
Fennec Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Fennec Pharmaceuticals is extremely important. It helps to project a fair market value of Fennec Stock properly, considering its historical fundamentals such as Revenue. Since Fennec Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fennec Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fennec Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Fennec Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Fennec Pharmaceuticals reported 47.54 M of revenue. This is 99.38% lower than that of the Biotechnology sector and 93.6% lower than that of the Health Care industry. The revenue for all United States stocks is 99.5% higher than that of the company.
Fennec Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fennec Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fennec Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Fennec Pharmaceuticals by comparing valuation metrics of similar companies.Fennec Pharmaceuticals is currently under evaluation in revenue category among its peers.
Fennec Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fennec Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fennec Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Fennec Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Fennec Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Fennec Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Fennec Pharmaceuticals' value.| Shares | Gendell Jeffrey L | 2025-03-31 | 195.2 K | Northern Trust Corp | 2025-03-31 | 138.4 K | Dg Capital Management, Llc | 2025-03-31 | 84.2 K | Charles Schwab Investment Management Inc | 2025-03-31 | 61.1 K | Bank Of New York Mellon Corp | 2025-03-31 | 53.5 K | Hartford Financial Management Inc. | 2025-03-31 | 49.8 K | Goldman Sachs Group Inc | 2025-03-31 | 43.2 K | Bnp Paribas Arbitrage, Sa | 2025-03-31 | 41 K | Rhumbline Advisers | 2025-03-31 | 33.4 K | Southpoint Capital Advisors Lp | 2025-03-31 | 4.1 M | Solas Capital Management Llc | 2025-03-31 | 2.3 M |
Fennec Fundamentals
| Return On Equity | -10.06 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.47) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 216.1 M | ||||
| Shares Outstanding | 27.62 M | ||||
| Shares Owned By Insiders | 16.26 % | ||||
| Shares Owned By Institutions | 57.78 % | ||||
| Number Of Shares Shorted | 1.3 M | ||||
| Price To Earning | (3.82) X | ||||
| Price To Book | 57.93 X | ||||
| Price To Sales | 7.10 X | ||||
| Revenue | 47.54 M | ||||
| Gross Profit | 27.91 M | ||||
| EBITDA | 3.6 M | ||||
| Net Income | (70 K) | ||||
| Cash And Equivalents | 14.91 M | ||||
| Cash Per Share | 0.57 X | ||||
| Total Debt | 19.34 M | ||||
| Debt To Equity | 0.58 % | ||||
| Current Ratio | 5.12 X | ||||
| Book Value Per Share | (0.21) X | ||||
| Cash Flow From Operations | 26.98 M | ||||
| Short Ratio | 16.88 X | ||||
| Earnings Per Share | (0.53) X | ||||
| Target Price | 13.8 | ||||
| Number Of Employees | 32 | ||||
| Beta | 0.4 | ||||
| Market Capitalization | 219.42 M | ||||
| Total Asset | 44.95 M | ||||
| Retained Earnings | (219.68 M) | ||||
| Working Capital | 37.2 M | ||||
| Current Asset | 7.88 M | ||||
| Current Liabilities | 1.97 M | ||||
| Net Asset | 44.95 M |
About Fennec Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fennec Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fennec Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fennec Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fennec Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fennec Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fennec Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fennec Pharmaceuticals Stock:Check out Fennec Pharmaceuticals Piotroski F Score and Fennec Pharmaceuticals Altman Z Score analysis. For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.53) | Revenue Per Share | Quarterly Revenue Growth (0.66) | Return On Assets | Return On Equity |
The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.